Citi Pharma Bets Big on Veterinary Sector, Targets PKR 10B Turnover

Citi Pharma Limited has formally entered Pakistan’s veterinary healthcare market through its new subsidiary, Citi Veterinary Limited, which launched trading operations Friday with an ambitious plan to achieve PKR 10 billion in turnover within three years.

The company is rolling out 32 veterinary products, including vaccines, backed by letters of credit for eight key offerings to secure supply. Citi Veterinary projects sales of Rs1.5 billion in FY2025-26 with a 13% gross margin, a figure analysts see rising to 25% once in-house production ramps up in FY2026-27.

Citi Pharma has already submitted plant layout plans to Pakistan’s Drug Regulatory Authority and expects inspection by December. Trial production is slated for the final quarter of FY2025-26, with full-scale output early next fiscal year. Plans include Pakistan’s first dedicated veterinary API (active pharmaceutical ingredient) plant, a potential game-changer for import substitution.

The aggressive move positions Citi Pharma as a front-runner in a largely untapped veterinary pharmaceuticals market, leveraging its established Chinese supply partnerships. The diversification could act as a catalyst for CITI’s stock, which analysts say may attract growth investors eyeing exposure to Pakistan’s expanding agribusiness sector.

Similar Posts